Physician profile
Syed Khalid
NPI 1790006393
$1,276.10
in general payments reported to CMS, 2019-2025
23 companies · $57.45 in 2025
The $57.45 reported for 2025 was less than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $260 · 2021: $14.36 · 2022: $29.11 · 2023: $45.67 · 2024: $400 · 2025: $57.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $502.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $240.01 | 2024-2025 | Expedium, Spine & Trauma 3d Navigation, Conduit |
| Novartis Pharmaceuticals Corporation | $215.49 | 2019-2024 | |
| Astellas Pharma US INC | $116.48 | 2020-2024 | Xtandi |
| Merck Sharp & Dohme LLC | $89.96 | 2019-2024 | Keytruda |
| Amgen INC. | $70.45 | 2019-2020 | |
| Tesaro, INC. | $56.67 | 2019 | |
| Seagen INC. | $54.02 | 2021-2023 | Padcev |
| Pfizer INC. | $45.80 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.96 | 2019-2020 | |
| Lilly USA, LLC | $38.92 | 2019-2024 | Retevmo |
| Array Biopharma INC | $37.41 | 2019-2024 | Xalkori, Lorbrena, Braftovi |
| Tolmar Pharmaceuticals, INC. | $35.38 | 2019-2020 | |
| Daiichi Sankyo INC. | $34.82 | 2019-2020 | |
| Helsinn Therapeutics (U.S.), INC. | $28.30 | 2019 | |
| Emd Serono, INC. | $27.84 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $23.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $20.66 | 2020 | |
| Kyowa Kirin, INC. | $19.41 | 2019 | |
| Cormedix INC. | $19.10 | 2024 | Defencath |
| Lexicon Pharmaceuticals, INC. | $18.75 | 2019 | |
| Taiho Oncology, INC. | $15.80 | 2019 | |
| Chiesi USA, INC. | $14.79 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.